natgillin/translations-raw huggingface dataset:
if the encoding process used adaptive hybrid transform processing for the respective channel: 
ako je postupak kodiranja koristio adaptivnu hibridnu transformacijsku obradu za odgovarajući kanal:
if the respective audio block is the first audio block in the frame: 
ako je odgovarajući audio blok prvi audio blok u okviru:
obtaining all hybrid transform coefficients of the respective channel for the frame from the encoded audio data in the first audio block, and 
dobivanje svih hibridnih transformacijskih koeficijenata za odgovarajući kanal za okvir iz kodiranih audio podataka u prvom audio bloku, te
applying an inverse secondary transform to the hybrid transform coefficients to obtain inverse secondary transform coefficients, and 
primjene inverzne sekundarne transformacije na hibridne transformacijske koeficijente da se dobiju inverzni sekundarni transformacijski koeficijenti, i
obtaining primary transform coefficients from the inverse secondary transform coefficients for the respective channel in the respective audio block; 
dobivanje primarnih transformacijskih koeficijenata iz inverznih sekundarnih transformacijskih koeficijenata za odgovarajući kanal u odgovarajućem audio bloku;
if the encoding process did not use adaptive hybrid transform processing for the respective channel, obtaining primary transform coefficients for the respective channel by decoding the encoded data in the respective audio block; and 
ako postupak kodiranja nije koristio adaptivnu hibridnu transformacijsku obradu za odgovarajući kanal, dobivanje primarnih transformacijskih koeficijenata za odgovarajući kanal pomoću dekodiranja kodiranih podataka u odgovarajućem audio bloku; te
applying an inverse primary transform to the primary transform coefficients to generate an output signal representing the respective channel in the respective audio block, wherein 
primjenu inverzne primarne transformacije na primarne transformacijske koeficijente da se dobije izlazni signal koji predstavlja odgovarajući kanal u odgovarajućem audio bloku.
A process for preparing cortexolone-17a-propionate in crystalline form I, wherein said crystalline form I is characterized by a DRX spectrum as represented in Figure 1 and by a DSC spectrum as represented in Figure 2 and by an IR spectrum as represented in Figure 3, said process comprising reacting a compound of Formula II: with a compound of Formula III R'OH (III) in the presence of a lipase from Candida, wherein R is CH3-CH2, and R' is a linear aliphatic chain containing 1-10 carbon atoms to give cortexolone-17a-propionate, and crystallizing said cortexolone-17a-propionate from tert-butylmethylether, to give cortexolone-17a-propionate in crystalline form I. 
Postupak dobivanja korteksolon-17a-propionata u kristalnom obliku III, gdje je navedeni kristalni oblik III naznačen time što ima DRX spektar, kao što je prikazan na Slici 7 ili 10 ili 13, što ima DSC spektar, kao što je prikazan na Slici 8 ili 11 ili 14, te što ima IR spektar, kao što je prikazan na Slici 9 ili 12 ili 15, gdje se navedeni postupak sastoji u reakciji spoja formule II [image], u organskom otapalu sa spojem formule III R′OH (III), u prisutnosti lipaze iz kvasca Candida, gdje R je CH3-CH2, a R′ je nerazgranati alifatski lanac, koji sadrži 1-10 atoma ugljika, kako bi se dobilo korteksolon-17a-propionat, te kristaliziranju navedenog korteksolon-17a-propionata iz smjese diklormetan/n-heksan, ili smjese aceton/n-heksan ili smjese etanol/voda, kako bi se dobilo korteksolon-17a-propionat u kristalnom obliku III.
The process according to claim 1, wherein R' is an aliphatic chain containing I - 8 carbon atoms. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što je R′ alifatski lanac, koji sadrži 1-8 atoma ugljika.
The process according to anyone of claims 1 to 11, wherein said lipase from Candida is present at an amount varying from about 100 to 1,000,000 U/mmol. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što navedena lipaza iz kvasca Candida dolazi u rasponu količina od otprilike 100 do 1.000.000 U/mmol.
The process according to claim 12, wherein said lipase from Gandida is present at an amount ranging from about 1,000 to 1,000.000 U/mmol for Candida cylindracea (CCL), and ranges from about 100 to 100,000 U/mmol for Candida antartica of type B (CALB). 
Postupak u skladu s patentnim zahtjevom 11, naznačen time što navedena lipaza iz kvasca Candida dolazi u rasponu količina od otprilike 1.000 do 1.000.000 U/mmol za kvasac Candida cylindracea (CCL), te u rasponu od otprilike 100 do 100.000 U/mmol za kvasac Candida antartica tip B (CALB).
A conjugate according to claim 17 or 18, wherein said cell binding agent is chosen from monoclonal antibodies; single chain antibodies; fragments of antibodies such as Fab, Fab', F(ab')2 and Fv, interferons; peptides; lymphokines such as IL-2, IL-3, IL-4, IL-6; hormones such as insulin, TRH (thyrotropin releasing hormones), MSH (melanocyte-stimulating hormone), steroid hormones, such as androgens and estrogens; growth factors and colony-stimulating factors such as EGF, TGFa, insulin like growth factor (IGF-I, IGF-II) G-CSF, M-CSF and GM-CSF; vitamins, such as folate and transferrin. 
Konjugat u skladu s patentnim zahtjevom 3 do 8, naznačen time što se navedeno sredstvo za vezanje na stanicu bira između monoklonskih protutijela; kimernih protutijela; humaniziranih protutijela; posve ljudskih protutijela; jednolančanih protutijela; fragmenata protutijela, poput Fab, Fab′, F(ab′)2 i Fv, interferona; peptida; limfokina, poput IL-2, IL-3, IL-4, IL-6; hormona, poput inzulina, TRH (tireooslobađajućih hormona), MSH (melanostimulirajućeg hormona), steroidnih hormona, poput androgena i estrogena; čimbenika rasta i čimbenika stimulacije kolonija, poput EGF, TGFa, inzulinu sličnog čimbenika rasta (IGF-I, IGF-II) G-CSF, M-CSF i GM-CSF; vitamina, poput folata i transferina.
wherein V is absent or is an amino acid sequence of at least one amino acid; 
pri čemu V je odsutan ili je aminokiselinski slijed sa barem jednom aminokiselinom;
The alkaline phosphatase of claim 1, wherein the spacer comprises a fragment crystallizable region (Fc), preferably wherein the Fc comprises a CH2 domain, a CH3 domain and a hinge region, or wherein the Fc is a constant domain of an immunoglobulin selected from the group consisting of IgG-1, IgG-2, IgG-3 and IgG-4, preferably wherein the Fc is a constant domain of an immunoglobulin IgG-1. 
Alkalna fosfataza prema zahtjevu 1, naznačena time da Fc sadrži CH2 domenu, CH3 domenu i zglobnu regiju, ili pri čemu Fc je konstantna domena imunoglobulina odabrana iz skupine koja sadrži IgG-1, IgG-2, IgG-3 i IgG-4, gdje je poželjno Fc konstantna domena imunoglobulina IgG-1.
Y is two amino acid residues, preferably wherein Y is leucine-lysine; and/or 
Y je dva aminokiselinska ostatka, poželjno pri čemu Y je leucin-lizin; i/ili
X is two amino acid residues, preferably wherein X is aspartate-isoleucine. 
X je dva aminokiselinska ostatka, poželjno pri čemu X je aspartat-izoleucin.
A pharmaceutical composition comprising the alkaline phosphatase of any one of claims 1 to 10 and a pharmaceutically acceptable carrier, preferably wherein the pharmaceutically acceptable carrier is a saline, more preferably wherein the alkaline phosphatase is in a lyophilized form. 
Farmaceutski pripravak naznačen time da sadrži alkalnu fosfatazu prema bilo kojem zahtjevu od 1 do 10 i farmaceutski prihvatljiv nosač, pri čemu poželjno farmaceutski prihvatljiv nosač je fiziološka otopina, te poželjnije pri čemu je alkalna fosfataza u liofiliziranom obliku.
The alkaline phosphatase for use of any of claims 19 to 21, wherein the use comprises transfecting a cell in the subject with a nucleic acid encoding the alkaline phosphatase, in particular wherein the transfecting the cell is performed in vitro such that the alkaline phosphatase is expressed and secreted in an active form and administered to the subject with said cell. 
Alkalna fosfataza za upotrebu prema bilo kojem zahtjevu od 19 do 21, naznačena time da se uporaba sastoji od transfekcije stanice koja kodira alkalnu fosfatazu u subjekt sa nukleinskom kiselinom, naročito gdje se transfekcija stanice provodi in vitro tako da se alkalna fosfataza eksprimira i izlučuje u aktivnom obliku i daje se subjektu sa navedenom stanicom.
The alkaline phosphatase for use of any one of claims 19 to 21, wherein the use comprises subcutaneous or intravenous administration of the alkaline phosphatase to the subject. 
Alkalna fosfataza za upotrebu prema bilo kojem zahtjevu od 19 do 21, naznačena time da se uporaba sastoji od potkožnog ili intravenoznog davanja alkalne fosfataze subjektu.
Z is absent or is an amino acid sequence of at least one amino acid; 
Z je odsutan ili je aminokiselinski slijed sa barem jednom aminokiselinom;
The alkaline phosphatase of claim 1, wherein the Fc comprises a CH2 domain, a CH3 domain and a hinge region, or wherein the Fc is a constant domain of an immunoglobulin selected from the group consisting of IgG-1, IgG-2, IgG-3, IgG-3 and IgG-4, preferably wherein the Fc is a constant domain of an immunoglobulin IgG-1. 
Alkalna fosfataza prema zahtjevu 1, naznačena time da Fc sadrži CH2 domenu, CH3 domenu i zglobnu regiju, ili pri čemu Fc je konstantna domena imunoglobulina odabrana iz skupine koja sadrži IgG-1, IgG-2, IgG-3 i IgG-4, gdje je poželjno Fc konstantna domena imunoglobulina IgG-1.
The alkaline phosphatase of any one of claims 1 to 10, wherein the alkaline phosphatase is in a pharmaceutically acceptable carrier, preferably wherein the pharmaceutically acceptable carrier is a saline, more preferably wherein the alkaline phosphatase is in a lyophilized form. 
Farmaceutski pripravak naznačen time da sadrži alkalnu fosfatazu prema bilo kojem zahtjevu od 1 do 10 i farmaceutski prihvatljiv nosač, pri čemu poželjno farmaceutski prihvatljiv nosač je fiziološka otopina, te poželjnije pri čemu je alkalna fosfataza u liofiliziranom obliku.
An isolated nucleic acid comprising or consisting of a sequence that encodes the polypeptide defined in any one of claims 1 to 8. 
Izolirana nukleinska kiselina koja sadrži ili se sastoji od sekvence koja kodira polipeptid prema bilo kojem zahtjevu od 1 do 8.
The alkaline phosphatase of any of claims 21 to 23, wherein the use comprises transfecting a cell in the subject with a nucleic acid encoding the alkaline phosphatase, in particular wherein the transfecting the cell is performed in vitro such that the alkaline phosphatase is expressed and secreted in an active form and administered to the subject with said cell. 
Alkalna fosfataza za upotrebu prema bilo kojem zahtjevu od 19 do 21, naznačena time da se uporaba sastoji od transfekcije stanice koja kodira alkalnu fosfatazu u subjekt sa nukleinskom kiselinom, naročito gdje se transfekcija stanice provodi in vitro tako da se alkalna fosfataza eksprimira i izlučuje u aktivnom obliku i daje se subjektu sa navedenom stanicom.
The alkaline phosphatase of any one of claims 21 to 23, wherein the use comprises intravenous administration of the alkaline phosphatase to the subject. 
Alkalna fosfataza za upotrebu prema bilo kojem zahtjevu od 19 do 21, naznačena time da se uporaba sastoji od potkožnog ili intravenoznog davanja alkalne fosfataze subjektu.
completely inactivating said collected virus directly after collection of the virus prior to any purification step and wherein the virus containing fluid or its non-viral constituents is (are) not further concentrated before said inactivating step, and 
potpuno deaktiviranje spomenutog prikupljenog virusa izravno nakon prikupljanja virusa, prije bilo kojeg koraka pročišćavanja, pri čemu tekućina koja sadrži virus ili svoje ne-virusne sastojke, nije dodatno koncentrirana prije spomenutog koraka deaktiviranja, te
treating said inactivated virus with detergent to produce a split virus vaccine, resulting in a preparation comprising viral antigens. 
obrada spomenutog deaktiviranog virusa s deterdžentom u svrhu proizvodnje razdvojenog virusnog cjepiva, koja rezultira s pripravkom koji sadrži virusne antigene.
The method of claim 1, wherein the concentration of non-viral protein during said inactivation is below 350 µg/ml. 
Postupak prema zahtjevu 1, naznačen time, da je koncentracija ne-virusnog proteina ispod 350 ng/ml, prilikom spomenutog deaktiviranja.
inactivating said collected virus from step (a), prior to any purification step of the virus and wherein the virus containing fluid or its non-viral constituents is (are) not further concentrated before said inactivating step, 
deaktiviranje spomenutog prikupljenog virusa iz koraka a) prije bilo kojeg koraka pročišćavanja virusa i pri čemu tekućina koja sadrži virus ili svoje ne-virusne sastojke, nije dalje koncentrirana prije spomenutog koraka deaktiviranja,
treating said inactivated virus with detergent to produce a split virus vaccine, and 
obrada spomenutog deaktiviranog virusa deterdžentom u svrhu proizvodnje razdvojenog virusnog cjepiva, te
The dispiro 1,2,4-trioxolane of claim 1 selected from the group consisting of compounds of formula (I), wherein R is selected from: 
Dispiro-1,2,4-trioksolan prema patentnom zahtjevu 1 izabran iz grupe koju čine spojevi formule (I), naznačen time da je R izabran od:
A pharmaceutical composition comprising a dispiro 1,2,4-trioxolane of claim 1 or 2 and a pharmaceutically acceptable carrier. 
[image] [image] Farmaceutski pripravak koji sadrži dispiro-1,2,4-trioksolan prema patentnom zahtjevu 1 ili 2 i farmaceutski prihvatljivi nosač.
The dispiro 1,2,4-trioxolane according to claim 6 whereby the trioxolane is to be administered before or after exposure to malaria. 
Dispiro-1,2,4-trioksolan prema patentnom zahtjevu 6, pri čemu se trioksolan primjenjuje prije ili nakon izlaganja uzročniku malarije.
The dispiro 1,2,4-trioxolane according to any one of claims 1 to 12 whereby the salt is selected from the group consisting of acetate, adipate, alginate, citrate, aspartate, benzoate, benzene sulfonate, bisulfate, butyrate, camphorate, camphor sulfonate, digluconate, glycerophosphate, hemisulfate, heptanoate, hexanoate, fumarate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethansulfonate (isothionate), lactate, maleate, methane sulfonate, nicotinate, 2-naphthalene sulfonate, oxalate, palmitoate, pectinate, persulfate, 3-phenylpropionate, picrate, pivalate, propionate, succinate, tartrate, thiocyanate, phosphate, glutamate, bicarbonate, p-toluene sulfonate and undecanoate salt. 
Dispiro-1,2,4-trioksolan prema bilo kojem od patentnih zahtjeva od 1 do 12 pri čemu je sol izabrana iz grupe koju čine acetat, adipat, alginat, citrat, aspartat, benzoat, benzen sulfonat, bisulfat, butirat, kamforat, kamfor sulfonat, diglukonat, glicerofosfat, hemisulfat, heptanoat, heksanoat, fumarat, hidroklorid, hidrobromid, hidrojodid, 2-hidroksietansulfonat (izotionat), laktat, maleat, metan sulfonat, nikotinat, 2-naftalen sulfonat, oksalat, palmitoat, pektinat, persulfat, 3-fenilpropionat, pikrat, pivalat, propionat, sukcinat, tartrat, tiocijanat, fosfat, glutamat, bikarbonat, p-toluen sulfonat i undekanoatna sol.
A method of manufacturing a composition for prophylaxis and treatment of malaria comprising: mixing a malaria prophylaxis or malaria treatment-effective amount of a dispiro 1,2,4-trioxolane, its prodrugs and optical isomers thereof, with a pharmaceutically acceptable carrier, said trioxolane being selected from the group consisting of: compounds of formula (I) Wherein R selected from: pharmaceutically acceptable salts, and combinations of the same. 
Postupak za proizvodnju pripravka za profilaksu i liječenje malarije koji obuhvaća: miješanje one količine dispiro-1,2,4-trioksolana koja predstavlja efektivnu dozu za profilaksu malarije ili za liječenje malarije, njegovih prolijekova i optičkih izomera, sa farmaceutski prihvatljivim nosačem, pri čemu je navedeni trioksolan izabran iz grupe koju čine: spojevi formule (I) [image] pri čemu je R odabran od:
A method for preparing concentrated protein products, wherein gels are produced by gelation at the first stage from aqueous suspensions of primary material sources at a concentration exceeding the critical gelation concentration, and, at the second stage, the resulting gels are further extracted by solvents extracting the sol fraction to yield an end target product that is a gel fraction having a three-dimensional net framework of protein molecules, wherein prior to extraction the surface area of the gels is increased further by water vapor explosion, freezing and subsequent removal of water from the microporous sponge gel, addition of food loosening agents, rapid release of pressure, or the cryotropic effect. 
Metoda za pripremu koncentriranih proteinskih proizvoda, naznačena time da se gelovi u prvoj fazi proizvode želiranjem iz vodenih suspenzija izvora primarnih materijala pri koncentraciji koja prelazi kritičnu koncentraciju za želiranje a drugoj se fazi dobiveni gelovi dodatno ekstrahiraju pomoću otapala koji ekstrahiraju sol frakciju da bi se dobio krajnji ciljni proizvod koji predstavlja gel frakciju koja ima trodimenzionalni mrežasti okvir proteinskih molekula, naznačena time da se prije ekstrakcije površina gelova dodatno povećava eksplozijom vodene pare, zamrzavanjem i zatim odstranjivanjem vode iz mikroporoznog spužvastog gela, dodavanjem sredstava za rahljenje hrane, brzim otpuštanjem pritiska ili kriotropskim efektom.
The method as claimed in claim 1, wherein the gel is prepared by a thermotropic, crystropic or baro-thermotropic gelation method. 
Metoda prema zahtjevu 1, naznačena time da se dotični gel priprema metodom termotropskog, kriotropskog ili barotermotropskog želiranja.
Protein products in the form of gel fractions having a three-dimensional net framework of protein molecules obtainable by the method of claim 1 or 2. 
Proteinski proizvodi u obliku gel frakcija koje imaju trodimenzionalni mrežni okvir proteinskih molekula koje se mogu dobiti metodom prema zahtjevu 1 ili 2.
Composed element according to claim 1, characterize in that the tongue (13) and groove (14) as well as the locking elements are made in one piece as profiled parts in the board material. 
Složeni element u skladu s patentnim zahtjevom 1, karakteriziran na način da su jezičak (13) i žlijeb (14) kao i elementi zaključavanja načinjeni u jednom komadu kao profilirani dijelovi u materijalu ploče.
Composed element according to claim 1 or 2, characterized in that the locking element (15) at the tongue (13) is situated entirely in the material of the respective outer layer (136). 
Složeni element u skladu s patentnim zahtjevom 1 ili 2, karakteriziran na način da je element zaključavanja (15) na jezičku (13) potpuno smješten u materijalu odgovarajućeg vanjskog sloja (136).
Composed element according to any of the preceding claims, characterized in that the locking element (16) at the groove (14) is situated entirely in the material of the respective outer layer (137). 
Složeni element u skladu s bilo kojim od prethodnih patentnih zahtjeva, karakteriziran na način da je element zaključavanja (16) u žlijebu (14) smješten potpuno u materijalu odgovarajućeg vanjskog sloja (137).
Composed element according to claim 6, characterized in that the locking element (16) at the groove (14) is situated entirely in the material of the respective outer layer (137). 
Složeni element u skladu s patentnim zahtjevom 6, karakteriziran na način da je element zaključavanja (16) u žlijebu (14) smješten potpuno u materijalu odgovarajućeg vanjskog sloja (137).
Composed element according to any of the preceding claims, characterized in that the corner connection forms an inner and an outer corner and that the tongue (13) and groove (14), are situated closer to the inner corner than to the outer corner. 
Složeni element u skladu s bilo kojim od prethodnih patentnih zahtjeva, karakteriziran na način da kutni spoj oblikuje unutarnji i vanjski kut i da su jezičak (13) i žlijeb (14) smješteni bliže unutarnjem kutu nego vanjskom kutu.
Composed element according to any of the preceding claims, characterized in that the tongue (13) is situated at the end face of the respective panel-shaped element (2), whereas the groove (14) is situated at a lateral surface of the respective panel-shaped element (3). 
Složeni element u skladu s bilo kojim od prethodnih patentnih zahtjeva, karakteriziran na način da je jezičak (13) smješten na kraju lica odgovarajućeg elementa u obliku panela (2), dok je žlijeb (14) smješten na bočnoj površini odgovarajućeg elementa u obliku panela (3).
Composed element according to claim 15, characterized in that the weight-reducing components comprise one or more materials of the following series: flax shives, particles of foamed synthetic material, peat. 
Složeni element u skladu s patentnim zahtjevom 15, karakteriziran na način da komponente koje smanjuju težinu sadrže jedan ili više materijala iz sljedeće serije: lanene trijeske, čestice pjenastog sintetičkog materijala, treset.
Composed element according to any of the preceding claims, characterized in that the particle board is provided with a coating (68), more particularly a melamine coatirig. 
Složeni element u skladu s bilo kojim od prethodnih patentnih zahtjeva, karakteriziran na način da je ploča iverice opskrbljena oblogom (68), točnije oblogom melamina.
Composed element according to claims 11 and 17, characterized in that such coating (68) is present at least at the surface in which the groove (14) is provided, and that, in coupled condition, it extends up to between the coupled panel-shaped elements (2-3), with the exception of the location where the groove is situated. 
Složeni element u skladu s patentnim zahtjevima 11 i 17, karakteriziran na način da je takva obloga (68) prisutna barem na površini u kojoj se nalazi žlijeb (14), i da se ona, u spojenom stanju, proteže do između spojenih elemenata u obliku panela (2-3), s iznimkom mjesta gdje se nalazi žlijeb.
A conveying system (1) according to any of claims 1 to 2, characterised in that the tube connection (2) includes a mechanical suction device (15) by which air is sucked and conducted away, where the air is sucked out immediately before a receiver station (4). 
Dostavni sustav (1) u skladu s bilo kojim od patentnih zahtjeva 1 do 2, karakteriziran na način da spoj cijevi (2) uključuje mehaničku usisnu napravu (15) kojom je zrak usisan i proveden dalje, gdje je zrak usisan odmah prije prihvatne stanice (4).
Use of a conveying system (1) according to any of claims 1 to 7, characterised in that the conveying system (1) is used for conveying up to a plurality of elongated items (9) at the same time where individual items (9) are sent in succession, the inner cross section of the tube having a size greater than the largest cross section of the item. 
Uporaba dostavnog sustava (1) u skladu s bilo kojim od patentnih zahtjeva 1 do 7, karakterizirana na način da se dostavni sustav (1)koristi za dostavu do množine izduženih stavaka (9) istovremeno gdje su pojedinačne stavke (9) poslane redom, unutarnji presjek cijevi ima veličinu veću od najvećeg presjeka stavke.
Use of a conveying system (1) according to claim 8, characterised in that the conveying system (1) is used for conveying items (9) where the items (9) are constituted by the material to be conveyed. 
Uporaba dostavnog sustava (1) u skladu s patentnim zahtjevom 8, karakterizirana na način da se dostavni sustav (1) koristi za dostavu stavaka (9) gdje su stavke (9) sačinjene od materijala koji treba dostaviti.
Use of a conveying system (1) according to claim 8 or 9, characterised in that the conveying system (1) is used for conveying items (9) constituted by containers, where a container contains e.g. 
Uporaba dostavnog sustava (1) u skladu s patentnim zahtjevom 8 ili 9, karakterizirana na način da se dostavni sustav (1) koristi za dostavu stavaka (9) sačinjenih od spremnika, gdje spremnik sadrži npr.
a blood sample or other sample, wherein the item (9) is conveyed from a dispatch station (3), and via the conveying system (1) sent to a receiver station (4) in connection with a laboratory. 
uzorak krvi ili drugi uzorak, pri čemu se stavka (9) dostavlja iz otpremne stanice (3) i putem dostavnog sustava (1) šalje do prihvatne stanice (4) u povezanosti s laboratorijem.